Saoirse O’Sullivan

Artelo Unvails New Data On ART26.12 Demonstrating Positive Effects In Multiple Models Of Neuropathic Pain

Professor Saoirse O’Sullivan, vice president of translational sciences at Artelo Biosciences, Inc.

Artelo Biosciences Reveals Positive Pre-Clinical Results Of ART26.12, A Novel FABP5 Inhibitor, In Alleviating Chemotherapy-Induced Pain

Professor Saoirse O’Sullivan, vice president of translational sciences at Artelo Biosciences Inc., (NASDAQ: ARTL) presented new research results entitled, “Discovery and pre